TMDX - Earnings announcements

ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2026. Recent HighlightsTotal revenue of $173.9 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025Net income of $7.3 million or $0.20 per fully diluted share in the first quarter of 2026Adjusted net income of $10.9 million or $0.30 per fully dilut

ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic c

ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025. Recent Highlights Total revenue of $160.8 million in the fourth quarter of 2025, a 32% increase compared to the fourth quarter of 2024Total revenue of $605.5 million in the full year 2025, a 37% increase compared to the full year 2024Generated net income of $105.4 m

ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (800) 7

ANDOVER, Mass., Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2025. Recent Highlights Total revenue of $143.8 million in the third quarter of 2025, a 32% increase compared to the third quarter of 2024Generated net income of $24.3 million or $0.66 per diluted share in the third quarter of 2025Owned 21 aircraft as of September 30, 2025; own

ANDOVER, Mass., Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for do

ANDOVER, Mass., July 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $157.4 million in the second quarter of 2025, a 38% increase compared to the second quarter of 2024Generated net income of $34.9 million or $0.92 per fully diluted share in the second quarter of 2025Received conditional Investigations Device

ANDOVER, Mass., July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for dome

ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565

ANDOVER, Mass., April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domesti

ANDOVER, Mass., Feb. 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2024. Recent Highlights  Total revenue of $121.6 million in the fourth quarter of 2024, a 50% increase compared to the fourth quarter of 2023Total revenue of $441.5 million in the full year of 2024, an 83% increase compared to the full year 2023Generated net income of $

ANDOVER, Mass., Feb. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844)

ANDOVER, Mass., Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $108.8 million in the third quarter of 2024, a 64% increase compared to the third quarter of 2023Generated net income of $4.2 million or $0.12 per diluted share in the third quarter of 2024Owned 18 total aircraft as of September 30, 2024

ANDOVER, Mass., Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 481-2832 for domes

ANDOVER, Mass., July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024. Recent Highlights  Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second quarter of 2023Generated net income of $12.2 million or $0.35 per diluted share in the second quarter of 2024Owned 15 total aircraft as of June 30, 2024Purc

ANDOVER, Mass., July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for dome

ANDOVER, Mass., April 30, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024. Recent Highlights  Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first quarter of 2023Generated net income of $12.2 million or $0.35 per fully diluted share in the first quarter of 2024OCS Heart and OCS Lung and associated new cli

ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domes

ANDOVER, Mass., Feb. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023. Recent Highlights  Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the full year of 2022Generated net income o

ANDOVER, Mass., Feb. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2023 after market close on Monday, February 26, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 80

ANDOVER, Mass., Aug. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2023. Recent Highlights  Net revenue of $52.5 million in the second quarter of 2023, a 156% increase compared to the second quarter of 2022.Transplant centers' use of the National OCS Program (NOP) drove approximately 93% of total U.S. OCS cases.Signed definitive agreement to acquire

ANDOVER, Mass., July 20, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2023 after market close on Thursday, August 3, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for dome

ANDOVER, Mass., May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023. Recent Highlights  Net revenue of $41.6 million in the first quarter of 2023, a 162% increase compared to the first quarter of 2022Transplant centers' use of the National OCS Program (NOP) drove approximately 91% of total U.S. OCS casesPublished Inaugural Environmental, Social,

ANDOVER, Mass., April 17, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2023 after market close on Monday, May 1, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic

ANDOVER, Mass., Feb. 22, 2023 /PRNewswire/ - TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2022. Recent Highlights  Total revenue of $31.4 million in the fourth quarter of 2022, a 225% increase compared to the fourth quarter of 2021Total revenue of $93.5 million in the full year of 2022, a 209% increase compared to the full year of 2021Appointed Nick Corcoran

ANDOVER, Mass., Feb. 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2022 after market close on Wednesday, February 22, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866)

ANDOVER, Mass., Oct. 20, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter of 2022 after market close on Thursday, November 3, 2022. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for

Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million ANDOVER, Mass., Aug. 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2022. The Company also announced it entered into a new $60 million five-year loan agreement with CIBC Innovation Banking ("CIBC"), which was fully funded upon closing.

ANDOVER, Mass., July 18, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter of 2022 after market close on Monday, August 1, 2022. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for dom

ANDOVER, Mass., May 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Net revenue of $15.9 million in the first quarter of 2022, a 125% increase compared to the first quarter of 2021Received FDA pre-market approval (PMA) of OCS™ DCD heart indication on April 28, 2022Results from the U.S. randomized OCS™ DCD Heart trial along wit

ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2022 after market close on Tuesday, May 3, 2022. The TransMedics management team will host a corresponding conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for domes

ANDOVER, Mass., Feb. 23, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2021. Recent Highlights Net revenue of $9.7 million in the fourth quarter of 2021, a 27% increase compared to the fourth quarter of 2020 Net revenue of $30.3 million in the full year 2021, an 18% increase compared to the full year of 2020 Launched commercialization of O

ANDOVER, Mass., Feb. 9, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23, 2022. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (833)

ANDOVER, Mass., Nov. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2021. Recent Highlights Net revenue of $5.4 million in the third quarter of 2021, a 24% decrease compared to the third quarter of 2020, driven primarily by the expiry of revenue contribution from clinical trials Received FDA 510(k) clearance for OCS Lung cold flush solution on J

ANDOVER, Mass., Oct. 26, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter after market close on Tuesday, November 9, 2021. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (833) 378-1026 for domestic

ANDOVER, Mass., Aug. 5, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2021. Recent Highlights Net revenue of $8.2 million in the second quarter of 2021, representing a 141% increase compared to the second quarter of 2020 Announced positive FDA advisory committee vote for OCS Liver System Received FDA 510(k) clearance of the OCS Lung Solution for use in

ANDOVER, Mass., July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Thursday, August 5, 2021. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (833) 378-1026 for do